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Abstract
Tumor necrosis factor-like weak inducer of apoptosis (TWEAK), along with its receptor fibro-
blast growth factor-inducible (Fn)14, is associated with various biological activities including
inflammation. However, its role in the pathogenesis of Graves’ orbitopathy (GO) is unknown.
In this study, we investigated the mechanism by which TWEAK regulates inflammatory sig-
naling in orbital fibroblasts from GO patients. We found that TWEAK and tumor necrosis
factor-α (TNFA) mRNA levels were upregulated in GO as compared to non-GO tissue sam-
ples. TWEAK, TNF receptor (TNFR)1, TNFR2, and TNFR superfamily member 12A mRNA,
and TWEAK and Fn14 protein levels were increased by interleukin (IL)-1β and TNF-α treat-
ment. Treatment with exogenous recombinant TWEAK increased the transcript and protein
expression of the pro-inflammatory cytokines IL-6, IL-8, and monocyte chemoattractant
protein-1 to a greater extent in GO than in non-GO cells, while treatment with the anti-Fn14
antibody ITEM4 suppressed TWEAK-induced pro-inflammatory cytokine release and hya-
luronan production. Additionally, the serum level of TWEAK was higher in Graves’ disease
patients with (341.86 ± 86.3 pg/ml) as compared to those without (294.09 ± 41.44 pg/ml)
GO and healthy subjects (255.33 ± 39.38 pg/ml), and was positively correlated with clinical
activity score (r = 0.629, P < 0.001) and thyroid binding immunoglobulin level (r = 0.659, P <
0.001). These results demonstrate that TWEAK/Fn14 signaling contributes to GO patho-
genesis. Moreover, serum TWEAK level is a potential diagnostic biomarker for inflammatory
GO, and modulating TWEAK activity may be an effective therapeutic strategy for suppress-
ing inflammation and tissue remodeling in GO.
Introduction
Graves’ orbitopathy (GO) is an inflammatory autoimmune disorder of the orbit associated
with Graves’ disease (GD) that occurs concurrently with thyroid dysfunction in about 40% of
cases[1]. An epidemiological study in the United States reported a GO incidence of 16/100,000
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in femaile and 2.9/100,000 in male [2], and among 237 GD patients seen at a single center in
Europe, 81.9% had no GO at baseline but 2.6% progressed to moderate-to severe GO, and
among 237 GD patients seen at a single center in Europe, 81.9% had no GO at baseline but
2.6% progressed to moderate-to-severe GO. Thyroid-stimulating hormone receptor (TSHR)
expressed in orbital fibroblasts is an autoimmune target in GO [3–6]. The binding of auto-
antibodies to orbital fibroblasts activates T cell-dependent inflammatory processes; activated
cluster of differentiation (CD)4+ T cells secrete interleukin (IL)-1, interferon-γ, and tumor
necrosis factor (TNF)-α, inducing the expression of TSHR and CD40 on the surface of orbital
fibroblasts and promoting the secretion of IL-6, IL-8, fibronectin, type I collagen, and glycos-
aminoglycans [7–9]. Interaction with CD4+ T cells enhances Graves’ orbital fibroblast activa-
tion, proliferation, differentiation, and fat accumulation; expansion of the fibroblast pool is
characterized not only by marked infiltration of activated lymphocytes, but also by increased
production of hydrophilic hyaluronan in response to cytokines [10,11].
Tumor necrosis factor-like weak inducer of apoptosis (TWEAK) is an apoptosis-inducing
ligand belonging to TNF superfamily that modulates various biological processes via its recep-
tor fibroblast growth factor-inducible (Fn)14, which is encoded by TNF receptor superfamily
member (TNFRSF)12A. TWEAK regulates inflammation, cell proliferation, angiogenesis, and
tissue repair and regeneration [12–14] and induces the production of pro-inflammatory mole-
cules—e.g., matrix metalloproteinase (MMP)1, IL-6, IL-8, monocyte chemotactic protein
(MCP)-1, and regulated upon activation normal T cell—that are expressed and secreted by
synoviocytes and fibroblasts as well as intercellular adhesion molecule (ICAM)-1, E-selectin,
IL-8, and MCP-1 by endothelial cells [14–17]. The pro-inflammatory effects of TWEAK/Fn14
are mediated by several signaling pathways including nuclear factor (NF)-κB, mitogen-acti-
vated protein kinase (MAPK), extracellular signal-related kinase (ERK)1/2, c-Jun N-terminal
kinase (JNK)1/2, and p38 cascades [18]. The TWEAK/Fn14 interaction is particularly impor-
tant in synovial inflammation associated with rheumatoid arthritis (RA); higher serum levels
of TWEAK, TNF-α, and IL-6 have been reported in RA patients as compared to normal con-
trols [19]. Furthermore, recombinant (r)TWEAK enhanced the production of MCP-1 and
macrophage inflammatory protein-2 by synovial cells in collagen-induced arthritis (CIA)
mice, whereas a monoclonal antibody (mAb) against TWEAK attenuated synovial prolifera-
tion and inflammatory cell accumulation in CIA [20]. Thus, blocking TWEAK signaling sup-
presses inflammation; in fact, studies of TWEAK and Fn14 knockout mice have shown that
this could be an effective treatment strategy for autoimmune diseases such as GO.
The present study investigated the mechanism by which TWEAK/Fn14 signaling contrib-
utes to the pathogenesis of inflammation in primary cultures of orbital fibroblasts from GO
patients. We found that pro-inflammatory cytokine and hyaluronan production by GO fibro-
blasts in primary cultures was increased in response to exogenous rTWEAK, an effect that was
abrogated by anti-Fn14 mAb. Moreover, serum TWEAK concentration was correlated with
clinical activity score (CAS) and TSHR Ab level in GO patients. Our data suggest that
TWEAK/Fn14 signaling plays a critical role in the pathogenesis of GO-related inflammation.
Materials and methods
Reagents and chemicals
Recombinant TWEAK, recombinant human IL-1β, and TNF-α were purchased from R&D
Systems (Minneapolis, MN, USA). Dulbecco’s Modified Eagle’s Medium (DMEM), fetal
bovine serum (FBS), penicillin, and gentamycin were from Hyclone Laboratories (Logan, UT,
USA). Anti-Fn14 mAb (ITEM4) was from eBioscience (SanDiego, CA, USA). Inhibitors of
MAPK kinase 1 (PD98059), p38 MAPK (SB203580), JNK (SP600125), phosphoinositide
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3-kinase (PI3K; LY294002), and NF-κB p65 (SC514) were purchased from Calbiochem (La
Jolla, CA, USA).
Subjects and tissue and cell preparation
Orbital tissue specimens were collected from patients during orbital decompression surgery
for severe GO (n = 11; eight women and three men, aged 39–55 years). Normal orbital tissue
was obtained over the course of orbital surgery for other non-inflammatory diseases from age-
and sex-matched control subjects with no history of autoimmune thyroid disease or GO
(n = 7; four women and three men, aged 34–53 years). The non-GO subjects underwent orbital
wall fracture surgery (n = 3), evisceration (n = 2), and orbital benign mass excision (n = 2).
The euthyroid status of GO patients was determined at the time of surgery, and patients had
not received steroid or radiation therapy for at least 3 months. Clinical information on GO
and non-GO patients is shown in Table 1.
Primary cultures of orbital fibroblasts were established as previously described [21]. Briefly,
orbital tissue explants were minced and placed in plastic culture dishes in DMEM:F12 medium
with 20% FBS and antibiotics. After orbital adipose tissue had grown out from the explants,
monolayers were serially passaged following trypsin/EDTA treatment and cells were incubated
in DMEM with 10% FBS and antibiotics. Cells between the second and fifth passages were
used for experiments.
Sera for analysis of TWEAK levels were obtained from 56 GO patients, 35 GD patients
without GO, and 39 healthy control subjects (S1 Table). All patients were recruited from the
Department of Ophthalmology at Severance Hospital, Seoul, Korea, and healthy controls were
age and sex-matched healthy control subjects. The institutional review board of Severance
Table 1. Clinical information of patient samples used in an in vitro study.
Age (years) sex CAS Smoker Duration of GO (years) Proptosis R/L (mm) Surgery performed
GO patients
46 M 3/7 y 1.6 20/21 Decompression
39 F 2/7 y 2.0 22/22 Decompression
40 M 0/7 n 2.2 21/20.5 Decompression
42 F 1/7 n 3.0 23/23 Decompression
48 F 0/7 n 3.2 18/18 Decompression
51 F 1/7 n 2.6 20/20 Decompression
52 M 2/7 y 1.5 24/24 Decompression
48 F 4/7 y 2.1 22.5/21 Decompression
55 F 3/7 n 1.8 22/22 Decompression
44 F 1/7 n 2.1 20.5/21 Decompression
42 F 0/7 y 2.4 23/23.5 Decompression
Non-GO control subjects
43 M 0 y n/a n/a evisceration
44 F 0 y n/a n/a orbital wall fracture
34 F 0 n n/a n/a evisceration
53 M 0 n n/a n/a orbital wall fracture
38 F 0 n n/a n/a orbital wall fracture
47 M 0 n n/a n/a orbital mass excision
42 F 0 n n/a n/a orbital mass excision
CAS, clinical activity score; GO, Graves’ orbitopathy; n/a, not applicable.
https://doi.org/10.1371/journal.pone.0209583.t001
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Hospital, Yonsei University College of Medicine (Seoul, Korea) approved the study and writ-
ten, informed consent was obtained from all participants after they had been provided with an
explanation of the nature and possible consequences of the study. This study protocol adhered
to the tenets of the Declaration of Helsinki.
CAS is based on the classical signs of inflammation and comprises seven items that are
scored from 0 to 7. TSHR Ab level was measured using third-generation thyrotropin-binding
inhibitory immunoglobulin (TBII) with the automated Cobas electrochemiluminescence
immunoassay (Elecsys; Roche Diagnostics GmbH, Penzberg, Germany) according to the man-
ufacturer’s instructions.
Real-time polymerase chain reaction (PCR)
Cells were cultured in 6-cm dishes until they reached confluence, at which time the culture
medium was replaced with serum-free DMEM. The cells were incubated for 24 h with either
10 μg/ml TNF-α or 10 μg/ml IL-1β. Total RNA was isolated and 1 μg of RNA was reverse tran-
scribed into complementary (c)DNA according to the manufacturer’s instructions. The cDNA
was used as the template for PCR amplification on an ABI StepOnePlus real-time PCR ther-
mocycler (Applied Biosystems, Foster City, CA, USA) using SYBR Green PCR reagent
(Applied Biosystems) and primers specific for TWEAK, TNFRSF12A, TNFA, TNF receptor
(TNFR)1, TNFR2, glyceraldehyde 3-phosphate dehydrogenase (GAPDH).
In separate experiments, PCR was performed using TaqMan universal PCR master mix to
quantitatively assess the transcript levels of IL6, IL8, MCP1, ICAM1, MMP1, MMP2, MMP7,
MMP9, and GAPDH in cell samples using the primers shown in S2 Table. PCR reactions were
performed in triplicate; target gene expression levels were normalized to that of GAPDH, and
the results are expressed as the fold change in cycle threshold (Ct) value relative to the control
group as determined with the 2−ΔΔCt method [22]. Data were included in the analysis only if Ct
was< 35. Results from at least three GO samples were compared with mean values of three
normal control samples.
Western blotting
Western blot analysis was performed as previously described [21] using antibodies against
TWEAK, Fn14, ERK, JNK, PI3K, v-Akt murine thymoma viral oncogene (Akt), and NF-κB
(Cell Signaling Technology, Danvers, MA, USA). TWEAK and Fn14 expression was measured
in orbital fibroblasts stimulated with IL-1β and TNF-α (10 ng/ml) for various times. To evalu-
ate the role of TWEAK in inflammatory signaling, orbital fibroblasts were treated with
TWEAK for different times and the relative amount of each protein was quantified by densito-
metric analysis of immunoreactive bands using ImageJ software (National Institutes of Health,
Bethesda, MD, USA), with values normalized to that of the β-actin signal of the same sample.
Enzyme-linked immunosorbent assay (ELISA)
Proinflammatory cytokine, hyaluronan, and TWEAK levels in the culture supernatant of con-
fluent orbital fibroblasts or in serum were determined using commercially available ELISA kits
(IL-6, IL-8, MCP-1, and hyaluronan: R&D Systems; TWEAK: Bender Medsystems, Vienna,
Austria) according to the manufacturers’ instructions. To investigate whether TWEAK-
induced cytokine production is dependent on Fn14, cells were incubated with the Fn14-speci-
fic mAb ITEM4 (2.5 μg/ml) prior to stimulation. For comparison, GO cells were exposed to
the signaling pathway inhibitors PD98059, SP600125, SB203580, and LY294002 (20 μM) and
SC514 (10 μM) for 1 h prior to stimulation with TWEAK. The production of hyaluronan
induced by TWEAK was analyzed in the same manner. Hyaluronan concentration in the
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sample was determined from a standard binding curve generated with known amounts of hya-
luronan. Samples were diluted 1:10 before analysis, and the mean value of triplicate samples is
reported.
To analyze serum level of TWEAK, blood samples were drawn into test tubes containing
10% (v/v) sodium citrate. Platelet-free plasma was obtained by centrifugation at 3000 × g for
15 min at room temperature and stored at −80˚C until analysis. Serum level of TWEAK pro-
tein (pg/ml) was measured using a commercial ELISA kit. Each sample was tested three times.
All serum samples were tested in the same assay.
Statistical analysis
Experiments were performed using cell samples from different donors, which were assayed in
duplicate. The mean and standard deviation were calculated from normalized measurements
of each mRNA or protein from multiple (at least three) samples harvested from different indi-
viduals. Data from a single cell group at different drug concentrations and incubation times
were evaluated with the Student t test or by analysis of variance using SPSS v.20.0 software
(SPSS Inc., Chicago, IL, USA). Pearson’s correlation coefficient was used to analyze the rela-
tionship between serum TWEAK concentration, CAS, and TBII level. A P value< 0.05 was
considered statistically significant.
Results
Expression of TWEAK and its receptor in orbital tissue and fibroblasts
To evaluate the expression of TWEAK and its receptor in GO, orbital tissue explants were
obtained from GO patients (n = 11) and non-GO healthy controls (n = 7), and relative TNFA,
TWEAK, TNFR1, TNFR2, and TNFRSF12A mRNA levels were analyzed by real-time PCR.
TWEAK and TNFA transcripts were upregulated in GO as compared to non-GO control tissue
(P< 0.05; Fig 1). There were no differences in the levels of other receptors or of TNFRSF12A
between the two groups, and TNFR1 was expressed at a similarly low level in all samples.
The expression of TWEAK and its receptors was assessed under inflammatory conditions
in GO (n = 3) and non-GO (n = 3) orbital fibroblast cultures following stimulation with IL-1β
or TNF-α by real time-PCR and western blot analyses. Treatment with IL-1β or TNF-α
increased TWEAK, TNFR1, TNFR2, and Fn14 mRNA (Fig 2) levels (P< 0.05) and TWEAK
and Fn14 protein levels in a time-dependent manner in both GO and non-GO cells (Fig 3).
Effect of rTWEAK on pro-inflammatory cytokine production
The expression of pro-inflammatory cytokines including IL-6, IL-8, and MCP-1—which are
implicated in the pathogenesis of GO—was examined at the transcript and protein levels by
real-time PCR and ELISA, respectively (Fig 4). Treatment with rTWEAK increased IL6, IL8,
Fig 1. TNFA, TWEAK, TNFR1, TNFR2, and TNFRSF12A (Fn14) expression in GO and non-GO orbital tissues. Transcript levels of TNFA as well as TWEAK and its
receptors TNFR1, TNFR2, and TNFRSF12A (Fn14) were compared between GO (n = 11) and non-GO (n = 7) orbital tissues by real-time PCR. TNFA and TWEAK were
upregulated in GO as compared to non-GO tissue. �P< 0.05 vs. non-GO control. NL, normal non-GO subjects.
https://doi.org/10.1371/journal.pone.0209583.g001
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and MCP1 mRNA (Fig 4A) and protein (Fig 4B and 4C) levels in GO cells relative to non-GO
cells in a time- and dose-dependent manner.
The mRNA expression of other cytokines including ICAM1, IL1B, and MMPs were ana-
lyzed in rTWEAK-treated GO cells by real-time PCR (Fig 5). ICAM1, MMP1, MMP2, MMP7,
and IL1B transcripts were upregulated in a dose-dependent manner after 6 h of rTWEAK
stimulation (P< 0.05; Fig 5A). In addition, ICAM1, MMP2, and MMP7 transcript levels were
increased after 24 h of rTWEAK treatment (P< 0.05; Fig 5B).
Involvement of Fn14 and intracellular signaling pathways in TWEAK-
mediated induction of pro-inflammatory cytokine production
TWEAK (10 ng/ml) treatment induced the expression of phosphorylated (p-)ERK1/2, p-Akt,
p-PI3K, p-JNK, and p-NF-κB p65 within 3 h in both GO and non-GO cells (Fig 6). Pretreat-
ment with 2.5 μg/ml anti-Fn14 mAb (ITEM4) for 1 h or with inhibitors of ERK, JNK, p38
MAPK, PI3K, and NF-κB signaling reduced IL-6, IL-8, and MCP-1 protein expression in-
duced by rTWEAK (100 ng/ml, 24 h) in GO cells (n = 3) (Fig 7). Fn14 blockade most potently
suppressed rTWEAK-induced cytokine production. These results indicate that Fn14—a spe-
cific TWEAK receptor—and other signaling proteins mediate the inflammatory effect of
TWEAK in GO orbital fibroblasts.
Effect of TWEAK on hyaluronan production
We investigated the effect of TWEAK on the production of hyaluronan, which is an important
step in the pathogenesis of GO. The release of hyaluronan into the culture medium following
treatment with 10–200 ng/ml TWEAK for 6 and 24 h was measured by ELISA. Hyaluronan
level was increased in GO cells upon stimulation with rTWEAK (Fig 8A). Pretreatment with a
mAb against Fn14 (ITEM4, 2.5 μg/ml) suppressed rTWEAK (100 ng/ml, 24 h)-induced hya-
luronan release (Fig 8B). Inhibition of JNK, p38 MAPK, PI3K, and NF-κB p65 (20 μM, 1 h)
pathways similarly reduced hyaluronan production.
Fig 2. Effect of IL-1β and TNF-α on TWEAK and Fn14 expression in GO and non-GO orbital fibroblasts. Cultured GO (n = 3, black columns)
and non-GO (n = 3, white columns) orbital fibroblasts were treated with IL-1β (10 ng/ml, first row) or TNF-α (10 ng/ml, second row) for 1, 3, 6, 16,
or 24 h. Data in the columns represent the mean fold difference in relative mRNA level ± standard deviation of triplicate measurements. �P< 0.05 vs.
untreated cells.
https://doi.org/10.1371/journal.pone.0209583.g002
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TWEAK protein level is elevated in the serum of GO patients
We measured serum TWEAK levels in GO patients (n = 56), GD patients without GO (n =
35), and age- and sex-matched healthy control subjects (n = 39). Mean age was similar among
groups (GO patients, 36.17 years; GD patients without GO, 34.34 years; and healthy subjects,
32.41 years). Mean serum levels of TWEAK were higher in GO patients (341.86 ± 86.3 pg/ml)
than in GD patients without GO (294.09 ± 41.44 pg/ml) (P < 0.05), who had higher levels than
healthy subjects (255.33 ± 39.38 pg/ml) (P< 0.05; Fig 9).
We examined the correlation between TWEAK level, CAS, and TSHR Ab level by Pearson’s
correlation analysis and found that serum TWEAK level was correlated with CAS (r = 0.629,
P< 0.001) and TBII level (r = 0.659 P < 0.001).
Fig 3. Effect of IL-1β and TNF-α on TWEAK and Fn14 protein levels in GO and non-GO orbital fibroblasts.
Cultured GO (n = 3) and non-GO (n = 3) orbital fibroblasts were treated with IL-1β (10 ng/ml) or TNF-α (10 ng/ml)
from 10 min to 24 h. TWEAK and Fn14 protein levels were evaluated by western blotting. (A) Representative gel
images. (B) Relative amount of each protein quantified by densitometric analysis of immunoreactive bands using
ImageJ software and normalized to the level of β-actin in the same sample (B). Data in the columns represent the mean
relative density ratio ± standard deviation of three experiments. �P< 0.05 vs. untreated cells.
https://doi.org/10.1371/journal.pone.0209583.g003
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Discussion
The results presented here demonstrate for the first time that TWEAK activates inflammation
and hyaluronan production in GO fibroblasts, and that blocking the TWEAK receptor Fn14
abrogates these effects. Cytokine release and hyaluronan production in orbital fibroblasts are
important steps in the initiation of exophthalmos and myopathy in the pathogenesis of GO.
We showed here that TNF-α and TWEAK levels were higher in GO than in non-GO orbital
tissues. Pro-inflammatory cytokines such as IL-1β and TNF-α induced the expression of
Fig 4. Effect of rTWEAK on mRNA and protein levels of IL-6, IL-8, and MCP-1 in GO and non-GO fibroblasts.
GO (n = 3, black columns) and non-GO (n = 3, white columns) orbital fibroblasts were treated with rTWEAK. (A, B)
IL6, IL8, and MCP1 mRNA levels were quantified by real-time PCR (A), and protein levels were quantified by ELISA
(B, C). Data in columns represent mean ± standard deviation. �P< 0.05 vs. untreated control cells.
https://doi.org/10.1371/journal.pone.0209583.g004
Fig 5. Effect of rTWEAK on ICAM1, MMP1, MMP2, MMP7, MMP9, and IL1B mRNA levels in GO cells. (A, B)
GO orbital fibroblasts (n = 3) were cultured and treated with rTWEAK (10 and 100 ng/ml) for 6 h (A) and 24 h (B).
ICAM1, MMP1, MMP2, MMP7, MMP7, MMP9, and IL1B mRNA levels were evaluated by real-time PCR. Data in
columns represent the mean fold difference in relative mRNA level ± standard deviation from triplicate measurements.
�P< 0.05 vs. untreated control cells.
https://doi.org/10.1371/journal.pone.0209583.g005
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TWEAK and its receptors TNFR-1, TNFR-2, and Fn14 in GO orbital fibroblasts. Conversely,
rTWEAK treatment increased the levels of the pro-inflammatory cytokines IL-6, IL-8, and
MCP-1, MMPs, and adhesion molecules such as ICAM-1 in orbital fibroblasts. In addition,
hyaluronan production by GO fibroblasts was enhanced by treatment with TWEAK, an effect
that was abolished by pretreatment with anti-Fn14 mAb. Fn14—which is induced in multiple
cell types during tissue injury—along with some intracellular signaling pathways were involved
in TWEAK-induced pro-inflammatory cytokine production. These findings provide evidence
for the role of TWEAK/Fn14 signaling in GO pathogenesis.
Serum level of TWEAK was elevated in GO patients as compared to GD patients without
GO and non-GO subjects; it was also positively correlated with CAS—a well-known indicator
of inflammation—and TBII, which predicts GO activity or severity.[23] Similar TWEAK levels
were observed between GO patients with and without radioiodine treatment, (357.33 vs. 337.4
pg/ml; P = 0.484). We presume that the radioiodine did not influence serum TWEAK level
since it was administered at least 6 months prior to study enrollment. It was reported that
serum TWEAK level was positively correlated with disease activity score-28 in RA patients
[19] and was associated with a lower incidence of pulmonary fibrosis and better pulmonary
function in systemic sclerosis patients.[24] Although the biological activity of TWEAK is com-
plex, it is known to be activated in inflammatory autoimmune disease and may serve as a reli-
able diagnostic and prognostic biomarker. Identifying new biomarkers and therapeutic targets
other than TSHR for GD and GO by combining microRNA and protein sequencing [25] can
improve our understanding of the pathogenesis of these disorders and lead to the development
of effective treatments.
Fn14 is a member of the TNFR family [26] that was identified as a functional TWEAK
receptor in a cDNA expression library screen [26]. Fn14 is expressed at a low level in various
cell types, and is induced under conditions of stress including inflammation. Several growth
factors, cytokines, and interleukins are known to induce Fn14 expression in injured endothe-
lial cells, vascular smooth muscle cells, monocytes, and macrophages but not in T and B lym-
phocytes [26,27]. TWEAK and Fn14 have been implicated in a variety of pathologies and their
extracellular localization makes them accessible pharmacological targets, with recombinant
soluble variants of or antibodies against these molecules showing high selectivity [24]. It
was recently demonstrated using an anti-human Fn14 mAb that TWEAK-induced cell
Fig 6. Effect of rTWEAK treatment on intracellular signaling in GO and non-GO cells. Cells were treated with
rTWEAK (10 ng/ml) for various times and cell lysates were analyzed by western blotting to assess p-ERK 1/2, p-Akt, p-
PI3K, p-JNK, and p-NF-κB p65 levels, with β-actin serving as a loading control.
https://doi.org/10.1371/journal.pone.0209583.g006
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proliferation, migration, and death was mediated by Fn14 [28–30]. TWEAK-specific antibod-
ies that block binding to Fn14 were generated by fusing the ectodomain of Fn14 and the Fc
domain of human IgG1. We found that blocking Fn14 using anti-Fn14 mAb suppressed
rTWEAK-induced cytokine production and hyaluronan release in cultured GO orbital
Fig 7. Role of Fn14 and intracellular signaling pathways in rTWEAK-induced pro-inflammatory cytokine expression.
IL-6, IL-8, and MCP-1 protein levels in GO orbital fibroblasts (n = 3) pretreated with ERK kinase (PD98059, 20 μM), JNK
(SP600125, 20 μM), p38 MAPK (SB203580, 20 μM), PI3K (LY294002, 20 μM), NF-κB p65 (SC514, 10 μM), and Fn14
(ITEM4, 2.5 μg/ml) inhibitor for 1 h followed by rTWEAK treatment (100 ng/ml, 24 h) were measured by ELISA. Data in
columns represent mean ± standard deviation of three experiments. �P< 0.05 vs. rTWEAK-treated cells without inhibitor
pretreatment.
https://doi.org/10.1371/journal.pone.0209583.g007
Fig 8. Effect of Fn14 inhibitor on rTWEAK-induced hyaluronan production in GO cells. Hyaluronan (ng/ml) level
in GO orbital fibroblasts (n = 3) was measured by ELISA after treatment with rTWEAK (10, 100 and 200 ng/ml) for 6
and 24 h. Cells (n = 3) were pretreated with ERK kinase (PD98059, 20 μM), JNK (SP600125, 20 μM), p38 MAPK
(SB203580, 20 μM), NF-κB p65 (SC514, 10 μM), and Fn14 (ITEM4, 2.5 μg/ml) inhibitor for 1 h followed by rTWEAK
treatment (100 ng/ml, 24 h). Data in columns represent mean ± standard deviation of three experiments. �P< 0.05 vs.
rTWEAK-treated cells without inhibitor pretreatment.
https://doi.org/10.1371/journal.pone.0209583.g008
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fibroblasts. Thus, TWEAK/Fn14 signaling plays a protective role in the acute stage of GO-asso-
ciated inflammation via suppression of cytokine and chemokine release in orbital fibroblasts.
TWEAK activates several signaling pathways that participate in the inflammatory response
in injured tissues. NF-κB plays a key role in TWEAK-induced inflammation [31–33]. TWEAK
also activates MAPK, ERK, JNK, and p38 pathways [17,34],[35] as well as PI3K/AKT signaling
in different cell types. TWEAK induction of JNK is related to activator protein-1 activation
[36]. Consistent with these reports, we found that TWEAK induced the phosphorylation of
ERK, Akt/PI3K, JNK, and NF-κB p65 in orbital fibroblasts. Furthermore, inhibiting these sig-
naling proteins blocked TWEAK-induced IL-6, IL-8, and MCP-1 expression and hyaluronan
production, which was similar to the suppressive effect of Fn14-blocking Ab, indicating that
TWEAK/FN14 signaling in the context of GO involves the ERK, Akt/PI3K, JNK, and NF-κB
p65 pathways.
Conclusions
The present study showed that TWEAK is expressed in GO orbital fibroblasts and may con-
tribute to orbital inflammation by inducing pro-inflammatory cytokine secretion. TWEAK
level was elevated in the serum of GO patients as compared to GD patients without GO and
non-GO subjects, and was positively correlated with clinical inflammation and TSHR Ab titer,
indicating that TWEAK is a potential biomarker for diagnosing inflammatory GO. In addi-
tion, we showed that inhibiting the TWEAK receptor Fn14 can alleviate TWEAK-mediated
Fig 9. Serum levels of TWEAK in GO patients, GD patients without GO, and normal subjects. Serum levels of TWEAK (pg/ml)
were higher in GO patients (n = 56) than in GD patients without GO (n = 35) and healthy subjects (n = 39). Data represent median
and interquartile range of values determined by ELISA. �P< 0.05 vs. each group.
https://doi.org/10.1371/journal.pone.0209583.g009
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GO pathology. Thus, our findings provide evidence that targeting TWEAK/Fn14 signaling
may be an effective therapeutic strategy for GO treatment.
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